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Autism Spectrum Disorders (ASDs) are a group of complex neurodevelopmental 
conditions characterized by abnormal patterns of attention, and impaired social and 
communication skills. ASDs are also associated with a number of functional 
challenges and potentially harmful deficits, including restricted and repetitive 
behaviors, anxiety, irritability, seizures, and self-harm. Although the exact causes of 
ASDs are currently unknown, it is suggested that genetic, epigenetic and 
environmental factors play critical roles. Recent findings support evidence for 
synaptic defects and impairments in brain information processing that are linked to 
social and perceptual skills. Owing to the clinical heterogeneity and lack of precise 
diagnostic tools, current therapeutic approaches aimed at managing ASD-associated 
conditions are not definitive. In this review, we seek to provide a contemporary 
account of the key pathological events pertaining to autism: the theory of oxidative 
stress and inflammatory causes; ideas of immune dysfunction; the probable 
biomarkers that can be used for diagnostics - and the use of pharmaceuticals and 
stem cells as possible candidates for the treatment of ASDs. 
 
Keywords: Autism spectrum disorders; Autism; Epigenetics; Stem cells; 
Nanoparticles; Neuroscience 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
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Autism spectrum disorders (ASDs) comprise a variety of neurodevelopmental 
conditions, characterized primarily by, impaired verbal and non-verbal 
communication skills, 1-4 a lack of social reciprocity, 5 and repetitive or restrictive 
behaviors and interests (APA’s DSM-5th Edition),  likely due to anatomical and 
physiological abnormalities in brain connectivity. 6,7 The ASDs are mainly grouped as 
follows: classical autism, atypical autism and Asperger's syndrome. 8,9 The two other 
closely related ASDs – Rett syndrome (RTT) and childhood disintegrative disorder 
(CDD) – show considerable symptom variation from the main ASD category. In both 
RTT and CDD, affected children initially demonstrate normal development, but over 
time show an impaired development of skills associated with interaction, language 
and coordination. 
 
The prevalence of ASDs is 1 – 1.5% in the US. 10,11 Males are more frequently 
affected than girls, with a one in 42 boys being diagnosed with an ASD compared to 
one in 189 girls. Despite the myriad studies conducted on ASDs thus far, the exact 
etiology and pathophysiology of these disorders remain poorly understood. 12-14 For 
instance, although increasing paternal and maternal ages at birth appear to increase 
the risk of a child developing autism,15 the underlying molecular processes linking 
this association to disease pathogenesis remain elusive. In addition, the clear 
heterogeneity of symptoms between affected individuals very likely reflects the 
heterogeneity of pathophysiological mechanisms in ASDs. This heterogeneity 
provides a significant hurdle to the development of broadly applicable diagnostic 
tools and therapies.  
 
However, recent studies have identified broad abnormalities such as synaptic 
connectivity problems, excitatory/inhibitory imbalances and white matter 
disorganization that may account for the impaired development of social and 
communication skills in children with autism. 16-18  Moreover, there is growing 
evidence that various genetic, epigenetic and environmental factors could account 
for a wide range of neurodevelopmental abnormalities seen in ASDs.1,19-21  
 
In this review, we will outline the main genetic, epigenetic and environmental factors 
implicated in the etiology of ASDs, followed by an overview of various biomarkers 
that may prove useful in the diagnosis of ASDs. We will end by discussing the 
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potential of certain drugs, stem cells and nanoparticles as therapeutic options in 
ASDs (Figure 1).  
 
Genetic/Epigenetic Factors in ASDs 
Advances in genetic tools have helped to clarify potential causative factors in autism 
by enabling the identification of genes associated with ASDs. 22-25 This genetic 
approach to elucidating the pathophysiology of ASDs has been adopted by various 
groups, who utilize a diverse array of investigations, including: copy number variation 
(CNV) 26-32; single nucleotide polymorphisms 33-36; tandem repeat polymorphisms 
(TRPs) 37; and twin births. 38,39  
 
These investigations have revealed ASD-associated mutations in a wide variety of 
genes that ultimately converge on several common biological pathways. For 
instance, many AD-associated genes appear to be linked directly or indirectly to 
synaptic plasticity and efficient neurotransmission. In a review of genome-wide 
association studies conducted so far, Glessner et al. highlighted that the risk for 
autism was significantly influenced by variation in a number of gene families 
encoding components in excitatory synapses, such as the neurexin (NRXN), 
CACNA, GRM, CNTN gene families.40  
 
Specifically, mutations in the neurexin (NRXN),41,42 as well as in the related 
neuroligin (NLGN) and ProSAP/Shank  gene families,43-48 have been shown to 
increase the risk for ASDs by altering synaptic structure and function. NLGNs are 
postsynaptic adhesion molecules that bind presynaptic NRXNs with high affinity. By 
connecting pre- and post-synaptic neurons, they facilitate trans-synaptic signaling 
and shape neural network properties. At the same time, members of the 
ProSAP/Shank family such ProSAP2/Shank3 appear to be involved not only in 
synaptic transmission through AMPA and NMDA receptors, but also in regulation of 
the density of presynaptic and postsynaptic proteins via neurexin–neuroligin trans-
synaptic signaling. ASD-associated mutations in any of these components (NRXNs, 
NLGNs, or ProSAPs/Shanks) could thus interfere with efficient trans-synaptic 
signaling and with maturation of excitatory synapses within the CNS.48   
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In addition to neuronal adhesive proteins, variation in genes involved in 
neurotransmitter function may significantly alter the risk for autism. For example, 
studies have proposed a link between the dopamine transporter (DAT1) gene and 
ASDs, and between the dopamine D4 receptor (DRD4) gene and autistic symptoms 
in children with attention-deficit/hyperactivity disorder (ADHD) 49. The former DAT1 
gene encodes presynaptic membrane protein is responsible for the high-affinity 
reuptake of synaptically released dopamine. The DAT protein is thus an important 
regulator of dopaminergic tone in the CNS. A de novo missense mutation in the 
DAT1 gene, which results in a Thr to Met substitution at site 356 (T356M), have 
recently been identified in patients with ASDs. This T356M variant is characterized 
by anomalous protein function, in which there is a persistent reverse transport of 
dopamine out of neurons. This process, known as substrate efflux, effectuates a 
major derangement in dopamine homeostasis, which in turn is thought to predispose 
to the development of ASDs and other psychopatholgies.50  
 
There is now growing recognition that variation in the epigenetic state of DNA across 
individuals may be a significant source of variation in the risk for autism. Briefly, 
epigenetics describes the molecular factors at regulatory regions of DNA that 
modulate gene expression without changing the primary DNA sequence itself. DNA 
methylation is perhaps the best understood epigenetic modification, where a methyl 
(-CH3) group is covalently attached to the cytosine of a CpG dinucleotide to 
downregulate gene expression. In this way, the expression level of a gene is hugely 
influenced by the epigenetic features of its surrounding regulatory regions.  
 
Some of the genes thought to be epigenetically different in ASDs are involved in 
important hormonal pathways. One such gene is the retinoic acid-related orphan 
receptor alpha (RORA) gene, a nuclear hormone receptor RORA that has dual roles 
in immune function and neurodevelopment. The RORA protein has been shown to 
transcriptionally regulate a number of genes, including NLGN1, NTRK2 (which 
encodes a catalytic receptor for neurotrophins), RBFOX1 (which encodes a splicing 
regulator for neuronal transcripts important for synaptic transmission and membrane 
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excitation), ITPR1 (which encodes a calcium channel implicated in the 
neurodegenerative disease infantile-onset spinocerebellar ataxia) as well as 
aromatase (or CYP19A1). It is thus conceivable that expression of all these 
downstream genes would be dysregulated by reduced expression of RORA, 
potentially leading to impairment of multiple neural pathways in autism.51  
 
Epigenetic regulation of RORA expression via differential DNA methylation has been 
observed in lymphoblastoid cell lines from discordantly diagnosed monozygotic twins 
and their nonautistic siblings. In the same study, the cerebellum and frontal cortex of 
autistic and age- and sex-matched control subjects revealed decreased expression 
of RORA in the autistic brain.52 The observation of similar methylation profiles in the 
brain and peripheral blood could suggest that epigenetic reprogramming is an early 
developmental event that occurs prior to germ layer specification. In this way, low 
levels of RORA during neurodevelopment due to DNA methylation could at least 
partially account for the defects in connectivity that thought to underlie the disease. 
Interestingly, the differential expression of RORA in male and female brains could 
explain the strong 4:1 male bias in ASDs 53; estrogen is known to increase RORA 
levels in the brain while testosterone decreases it. Since aromatase, which is 
activated downstream to RORA, is itself responsible for aromatizing testosterone to 
estrogen, this sets up a positive feedback loop of decreased RORA expression - 
which may predispose children with high testosterone and low estrogen levels to 
ASDs. This relationship is depicted in Figures 2 and 3.  
 
 
There is also evidence that methylation of the oxytocin receptor (OXTR) gene is 
associated with autism, high callous-unemotional (CU) traits, and differential 
activation of brain regions involved in social perception. 55 In one study, DNA 
methylation analysis of a CpG island known to regulate OXTR expression found that 
several CpG dinucleotides show increased DNA methylation in the peripheral blood 
cells and temporal cortex in independent datasets of autistic individuals, as 
compared to control samples. In agreement with these findings, the same study 
found decreased OXTR mRNA levels in the temporal cortex tissue of age- and sex-
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matched autistic individuals compared to controls. 56  
 
At present, our understanding of the chronology, regulation and reversibility of 
epigenetic programming during fetal development is limited. Future studies are 
necessary to determine whether loci such as the RORA and OXTR loci are 
epigenetically labile and susceptible to certain exposures in utero that alter the 
methylation status of these genes. A more thorough understanding of epigenetic 
changes during the first few weeks of pregnancy would help clarify how genes and 
the environment interact in the pathophysiology of ASDs.  
 
Environmental Risk Factors in ASDs 
It has been established that genetic, epigenetic and environmental causes are 
closely interlinked in non-syndromic ASDs. 57-63 Environmental challenges in 
particular are known to pose maximum risk during early development. 64 As would be 
expected, many of these environmental challenges are driven by maternal factors. 
Examples include: intake of prenatal and perinatal analgesics 65; teratogenic/toxic 
agents such as thalidomide, valproic acid, ethanol and misoprostol 66-68; frequent 
prenatal ultrasound recordings  inducing birth defects in early pregnancy 67; parental 
occupational hazards such as varnish, xylene and asphalt compounds 69; pre-term 
accumulation of trace metals such as lead, nickel, and arsenic 66,70-74; potential 
chemical hazards like organophosphorus pesticides, polychlorinated biphenyls 
(PCBs) and polyaromatic hydrocarbons (PAHs) 59,75; and highly mutagenic synthetic 
perfumes and cosmetics. 10 However, it is important to note that there are inherent 
difficulties in forming definitive links between environment influences and ASDs. For 
instance, although several lines of study have associated numerous trace metals 
with an increased risk for autism, a recent study cast doubt on this association by 
suggesting that only mercury is related to autism.76 Hence, the matter of labeling 
heavy metals as a risk factor for ASDs is contentious and remains unresolved.  
 
Immune Dysregulation, Oxidative Stress and Neuroinflammation  
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It has been established that problems with immune function are likely to contribute to 
the development of ASDs.77-80 In fact, immune dysfunctions, oxidative stress, 
mitochondrial abnormalities and neuroinflammatory processes appear to be mutually 
reinforcing in patients with ASDs. 81-84 Results from peripheral biomarker studies 
emphasize the key roles of both innate and adaptive immune system deregulation in 
ASDs. 85,86 Deregulated immune system genes in autistic subjects  seem to be 
important causes of behavioral problems, 85,87 as well as gastrointestinal 
complications. 88,89 Loss of blood brain barrier (BBB) integrity is one of the key 
pathological steps in the progression of immune dysfunction associated with ASDs. 
90,91
 Notably, mast cell activation may lead to gut-blood-brain barrier disruption, as 
well as brain inflammation. 92 
 
Using a mouse model of autism, drastic changes in various immune molecules have 
been observed 93; whilst clinical data suggest that pro-inflammatory cytokine levels 
can often be correlated with autistic behaviors. 94,95 Inflammatory cytokine alterations 
in subjects prone to environmental risks have been evident in several studies, 79,93,96 
and it is plausible that increased neuroinflammation provoked by elevated cytokines 
could contribute to observed behavioural dysfunction in autistic individuals. 97-100 
Th1-like (IFN-gamma, IL-2) cytokines have been found to be decreased and Th2-like 
(IL-4, IL-6, and IL-10) cytokines have been found to be increased in autistic children 
as compared to control groups. 101 An elegant transcirtomic analysisby Gupta et al, 
found that a gene expression module corresponding to M2-activation states in 
microglia was elevated in autism cases compared to controls. In addition, this M2-
activation state is negatively correlated with a neuronal module corresponding to 
synaptic transmission genes that appears to be differentially expressed in autism. 
The enrichment of genes corresponding to an M2-activation state and simultaneous 
attenuation of genes implicated in synaptic transmission implicating dysregulated 
microglial responses in concert with altered neuronal activity-dependent genes in the 
pathophysiology of autism during early development.102 
 
Furthermore, maternal IgG antibodies such as those produced in autoimmune 
disease (e.g. systemic lupus erythematosus) can cross the placenta to the fetus. 
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While these antibodies are less likely to cross the adult BBB, the developing BBB in 
the fetus is more permeable and hence more vulnerable to antibody-mediated 
damage, as shown in Figure 4. 96,103 In fact, Braunschweig et al. found a significant 
correlation between maternal IgG reactivity to fetal brain proteins and a childhood 
diagnosis of autism. 104 Altogether, the evidence suggests that environmentally 
driven peripheral immune dysfunctions and associated neuropathological 
consequences form a series of interlinked events, which can manifest in autistic 
features.  
 
As such, although there are a wide variety of genetic, epigenetic and environmental 
factors that have been implicated in ASDs, these factors are likely to eventually 
contribute to a specific underlying pathogenic mechanism – such as immune 
dysfunction – that may be targeted for diagnosis or therapy.  
 
Diagnostic Biomarkers for ASDs 
Within ASDs, a complexity of genetic polymorphisms, observed symptoms, and 
phenotypic variants exist, making it difficult to pinpoint a single biomarker with any 
real predictive value. Although a number of studies have attempted to find such 
biomarkers for ASDs, any promising and accurate diagnostic measures have yet to 
be established – and this remains a crucial, as of yet unresolved, step in the 
construction of targeted therapies for ASDs. Nonetheless, various categories of 
biomarkers have already been suggested to identify those at risk. At the hormonal 
level, plasma oxytocin (OT) and whole-blood serotonin (5-HT) levels are found to be 
consistently altered in individuals with ASD 105; whilst increased androgen 
(androstenediol, dehydroepiandrosterone, androsterone and their polar conjugates) 
and steroid hormones (both C21 and C19) in the saliva have also been found to be 
indicative of anxiety and other features witnessed in autistic children,106 and could be 
considered for diagnostic purposes. The latter has interesting wider correlates with 
neuropsychological theories of autism – such as the ‘hyper-male’ expansion of the 
empathizing versus systemizing dichotomy. Studies on thyroid hormone alterations 
are yet to establish significance among autistic subjects, though this remains a field 
of considerable interest. One review article implicates changes in basic biochemistry 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
(blood count, trace metals, thyroid and sex hormones and cholesterol tests) and 
transsulfuration biomarkers.107 It further describes decreases in levels of methylation, 
glutathione, transferrin, ceruloplasmin, carnitine and vitamin D, as well as increases 
in urinary 8-hydroxyguanine and isoprostane. Biomarkers of immune dysregulation 
such as altered serum antibodies to brain endovasculature, markers of cell-mediated 
immune activation (neopterin and biopterin), and increased levels of urinary N-
methylhistamine seem especially pertinent but lack accuracy. Decreased blood 
levels of essential fatty acids (EFA), 5-oxoproline and lactic acid, and increased 
blood levels of arginine and taurine metabolites are also considered as biomarkers. 
108
 Moreover, studies focusing on heavy metals as diagnostic biomarkers (increased 
blood and urinary levels of toxic metals and xenobiotics, RBC tests on toxic metals 
such as mercury, arsenic and lead) and gastrointestinal biomarkers (inflammation, 
urinary organic acids, gluten intolerance, food allergies) have also been reported. In 
other recent studies, variations in thyroid hormone (T4) levels and decreased 
tryptophan metabolism also offer clues for developing a potential diagnostic assay 
for ASDs. 109,110 
 
miRNAs, which are small endogenous molecules that bind mRNA and silence genes 
through the RNA-induced silencing complex, may also be useful diagnostic 
biomarkers for autism. Circulating miRNAs in the serum and plasma are known to be 
stable and are increasingly recognized as potential noninvasive biomarkers for 
neurological and neurodevelopmental disorder. One study found that thirteen 
miRNAs were differentially expressed in autistic and non-autistic children, as shown 
in Figure 5. 111 Using receiver operating characteristic curve analysis to evaluate the 
trade-off between sensitivity and specificity in diagnostic tests,112 the study authors 
found that five of these miRNAs (miR-181b-5p, miR-320a, miR-572, miR-130a-3p 
and miR-19b-3p) were highly sensitive and specific for autism.  
 
In keeping with the theme of minimally invasive, peripheral biomarkers for the central 
neuropsychiatric abnormalities in ASDs, microarray work in peripheral blood 
mononuclear cells of infants have revealed an abnormal gene expression profile in 
these cells. The identification of sensitive and specific alterations in gene profiles 
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could form the basis of a simple, efficient and cost-effective blood-based biomarker 
for diagnosing autism. 113 Moreover, since epigenetic profiles undergo 
reprogramming during very early gestation (from fertilization to implantation), one 
would expect that differential epigenetic profiles in patients in autism would be 
observable in tissue of both ectodermal origin (nervous tissue) and mesodermal 
origin (peripheral blood cells).  The occurrence of a consistent and global epigenetic 
profile in cells of the CNS and the periphery is a crucial consideration in developing 
diagnostic tests based on tissue from more accessible sites in the body. In fact, 
future work on the safe and simple blood-based biomarkers may even culminate in 
the development of a routine blood spot test during childhood development to detect 
ASDs in a prompt and efficient manner.114 This would that ensure adequate medical, 
psychological and social support is provided as early as possible to children who 
develop autism, which in turn may help to alleviate symptom severity, alter the 
developmental trajectory, and improve the quality of life in autistic patients and their 
families.115  
 
 
The use of minimally invasive neuroimaging approaches to observe the disease 
process or outcome in autistic patients is another promising field of study.116-118 Brain 
imaging and monitoring methods such as structural magnetic resonance Imaging 
(MRI), functional MRI (fMRI), electroencephalography, and 
magnetoencephalography are expanding in use, and are already identifying 
potentially significant alterations in brain architecture and function in ASDs (such as 
atypical lateralization revealing both grey and white matter defects).119 Figure 6 
illustrates deviant auditory processing in response to an unexpected auditory 
stimulus in two autistic individuals. In this study, it was proposed abnormal cortical 
activation in the superior frontal gyrus, posterior temporal lobe, and superior and 
inferior parietal lobule may form a neural basis for the resistance to unexpected 
change in the environment in autism. In addition, another group found that multi-
voxel pattern analysis (MVPA) by fMRI could be used to predict the severity of 
clinical symptoms of autism. Here, patients with ASD showed fusiform gyrus 
hypoactivation when presented with unfamiliar faces, compared to controls. The 
subnormal level of activation in the area of the brain primarily responsible for facial 
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recognition might underlie the defective face processing in individuals with ASD. 
More importantly, a reliable correlation was observed between MVPA classification 
performance and standardized measures of symptom severity, a finding which could 
support the use of fMRI in diagnosing and classifying ASDs.120 
 
Thinking Small: Small Molecules for the Treatment of ASDs 
 
The progress in our understanding of the mechanistic underpinnings of ASDs has 
undoubtedly guided efforts to design effective treatments. To this end, many 
potential small molecule drugs have been tested for their potential to manage 
symptoms in ASDs. Unfortunately, there has been limited success with any of the 
compounds screened in pilot studies and clinical trials so far. Hence, it seems 
reasonable that a more systematic and methodical approach to search for potential 
treatments is necessary – for instance, priority should be given to developing 
accurate biomarkers, before screening a wide range of compounds. This sequential 
approach would not only reduce fiscal cost, but also save time and manpower.  
 
Drugs that modulate neurotransmitter function have been extensively used in 
neuropsychiatric conditions, Recently, alpha2A adrenoceptor agonists such as 
clonidine and guanfacine have shown promise in improve symptoms of hyperactivity 
in autistic patients 122. In fact, an extended-release formulation of guanfacine (GXR) 
has already entered phase III trials in children with ADHD. Similarly, small, controlled 
studies have indicated a possible improvement in symptoms of hyperactivity in 
autistic patients given of the psychostimulant methylphenidate.123 Methylphenidate is 
a noradrenaline-dopamine reuptake inhibitor that increases catecholamine levels in 
the brain, and is being extensively studied as treatment in ASDs, either in its own 
right or in conjunction with other drugs. In fact, an ongoing trial is investigating the 
concomitant use of methylphenidate and guanfacine in autistic patients.  
 
It is worth noting that the mechanism of action of many promising drugs, as well as 
their effected changes in neurotransmitter levels of such, are diverse and in some 
instances contradictory. For instance, guanfacine is thought to decrease overall 
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noradrenergic tone while methylphenidate increases it. This observation reflects the 
fact that our understanding of the underlying deficits in ASDs, and of how exactly 
these drugs achieve their therapeutic effect, it is still unclear. What is clear, however, 
is that because these drugs alter crucial signaling pathways within the brain, adverse 
effects are almost inevitable. For instance, alpha2A-agonists are associated with 
sedation and cardiovascular effects due to the decreased noradrenaline levels within 
the locus coeruleus and vasomotor center of the brain, respectively. In addition, 
selective serotonin reuptake inhibitors such as fluvoxamine and fluoxetine have been 
shown to provide limited improvement of ASD symptoms, probably by increasing 
synaptic concentrations of serotonin, which is thought to enhance synaptogenesis. 
Low-dose liquid fluoxetine has been shown to moderately reduce repetitive 
behaviors in childhood and adolescent ASDs in a small clinical trial; however, long-
term trials are needed to replicate the results,124 and the limited benefit may not be 
convincing enough to justify the risk of adverse side effects, such as disinhibition 
syndrome and agitation.125,126 
 
The better side-effect profile and promising preliminary data from trials on 
metabotropic glutamate receptor (mGluR) antagonists suggests that they may be 
promising pharmacological agents in the treatment of ASDs. In mouse studies, a 
mGluR antagonist, 2-methyl-6-(phenylethynyl)-pyridine (MPEP), has been shown to 
enhance social behavior networks in an autistic Balb/c mouse model.127 At the same 
time, synaptic defects and LTD problems were ameliorated by a group II mGluR 
antagonist in a mouse model of Fragile X syndrome, which is trelated to the ASDs.128 
In phase II trials, metabotropic glutamate receptor (mGluR) antagonists seem to 
improve socio-behavioral symptoms in ASDs and Fragile X syndrome.129-131 These 
agents thus signify substantial progress towards novel clinically applicable 
therapeutics.  
 
Many convincing reports emphasize that antipsychotics such as haloperidol and 
risperidone can reduce the majority of ASD symptoms at relatively low doses. For 
instance, the first placebo-controlled trial of risperidone in autism, which involved 31 
adults with ASDs, found that risperidone at a mean dose of 2.9 mg/d was 
significantly more efficacious than placebo. Fifty-seven per cent subjects on 
risperidone showed an improvement in the Clinical Global Impression–Improvement 
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scale, compared to none of the subjects on placebo. Specifically, risperidone 
appeared to reduce repetitive behavior as well as aggression toward the self, others, 
and property. However, although antipsychotics offer some promise, extrapyramidal 
side effects such as tardive dyskinesia with typical antipsyhcotics, as well as 
metabolic side effects such weight gain and dyslipidaemia with atypical 
antipsychotics, remain a major concern.123 
 
Other drugs being newly explored as potential therapeutic options include 
thiazolidinediones such as pioglitazone that are used in type 2 diabetes.1,132 
Pioglitazone acts as an agonist to peroxisome proliferator activated receptor-gamma 
(PPAR-γ), and while it is often used to improve insulin sensitivity in diabetic patients, 
it has also demonstrated considerable benefit by suppressing symptoms associated 
with autistic behavior.1,133 Pioglitazone may achieve this therapeutic effect in ASDs 
by inducing apoptosis in activated T-lymphocytes and exerting anti-inflammatory 
effects in glial cells. These functions counteract the immune dysfunction that is 
thought to underlie ASD pathophysiology. In addition, studies have reported benefits 
of vitamin B6 therapy in ASDs for about three decades. Vitamin B6 is thought to 
balance specific metabolic pathways in neuronal cells, such as the methionine cycle, 
and is required for innumerable enzymatic reactions, including neurotransmitter 
synthesis and the production of glutathione for detoxification. Magnesium 
supplementation with vitamin B6 may help prevent hyperactivity and vitamin B6-
induced peripheral neuropathy. A Cochrane meta-analysis in 2005 was unable to 
find significant evidence supporting the use of vitamin B6-Mg in ASDs due to the 
methodological quality and small number of trails available.134 As such, more 
comprehensive trials are required to evaluate the beneficial and harmful effects of 
agents such as PPAR-γ agonists and vitamin B6 in treating ASDs.  
 
Nano-Pharmaceuticals: Expanding the Therapeutic Toolbox  
 
Given the limitations of currently available small molecule drugs, it seems that novel 
agents with unique mechanisms of action are necessary. Nanoparticles may provide 
a springboard for new pharmacological agents, particularly because they would 
facilitate efforts to address the dysregulated immune activity and oxidative stress that 
have been implicated in autism.  
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In this regard, gold nanoparticles (AuNPs) are an interesting pharmaceutical 
candidate. Ghanizadeh et al. suggest that the administration of AuNPs with lipoic 
acid may alleviate symptoms of autism through numerous anti-inflammatory and 
anti-oxidant mechanisms, such as increasing glutathione peroxidase (GPx) activity 
and increasing the scavenging of free radicals.135 This suggestion was corroborated 
by another study which found that AuNPs increased expression of anti-oxidant 
enzymes GPx, superoxide dismutase and catalase, with an associated increase in 
the plasma oxygen radical absorbance capacity of autistic mice.136  
 
Furthermore, Kannan et al. conducted a study in which the well-established anti-
inflammatory drug N-acetyl-cysteine (NAC) was conjugated to polyamidoamide 
(PAMAM) dendrimers and injected into newborn rabbits with cerebral palsy.137 They 
noted a rapid decrease in neuroinflammation and oxidative damage within 5 days of 
administration, as shown in Figure 7 137; given that autism is characterized by a 
similar neuroinflammatory process, they propose that NAC-conjugated dendrimers 
have the potential to be developed as a possible treatment for autism. Interestingly, it 
has been noted that there is normally no observable transplacental movement of G4-
OH PAMAM dendrimers in humans.137 This means that prenatal therapies utilizing 
these dendrimers can be confined specifically to either the maternal or fetal 
compartment, allowing for separate regulation of maternal and fetal factors involved 
in autism.    
 
It is worth emphasizing that although nanoparticles may be exquisitely suited to treat 
ASDs due to their unique structural and biochemical features, they may also offer an 
unprecedented sensitivity and resolution in in vivo biological imaging. For example, 
the superior optical properties and greater versatility in protein targeting of quantum 
dots, compared to conventional chemical labels, would be particularly useful in 
neuroimaging. Many studies have already deployed quantum dots to image neuronal 
proteins like the serotonin and dopamine transporters, as well areas of oxidative 
stress – and these are all parameters that are potentially altered in ASDs.138 This 
imaging method has notable advantages over traditional methods, in terms of 
minimizing ambiguities and discrepancies. As such, it should be remembered that 
nanoparticles are useful not just their direct therapeutic benefits, but also for their 
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potential role in visualizing anatomical or physiological variables within the brain, 
which in turn could inform other therapeutic interventions.   
 
Stem Cell Therapy: Hype or Hope? 
Currently, the approved therapies for ASDs alleviate the behavioral and physiological 
symptoms without targeting the underlying pathological causes. There is an urgent 
need for new and better targeted therapies, and stem cell therapy presents a 
particularly promising approach.139 Stem cell technology has expanded over time to 
target a wide range of neurpsychiatric disorders,140-143 including ASDs.141,144-148 
 
Very recently, an exciting study found that bone marrow transplantation could offer 
therapeutic promise in Rett syndrome and possibly other ASDs. Here, engraftment of 
brain parenchyma by bone marrow-derived myeloid cells of microglial phenotype 
occurred after transplantation of wild type bone marrow into irradiation-conditioned 
Mecp2-knockout. These donor bone marrow-derived microglia were capable of 
restoring neural function in ASD-model Mecp2 knockout mice, potentially by 
counterbalancing dysregulated inflammatory pathways that occur in ASDs. This 
microglial engraftment was also associated with an arrest of disease development. 
Interestingly, the benefits mediated by wild type microglia were diminished with 
pharmacological inhibition of phagocytic activity. This study thus supports the notion 
that dysregulated immunity is an important aspect of the development and/or 
progression of ASDs, and that that bone marrow stem cell transplantation might 
alleviate this pathological factor by augmenting phagocytic activity in the brain.149 
 
While bone marrow transplantation may indeed by a feasible treatment for ASDs, 
studies in humans have focused instead on the targeted local delivery of stem cells 
within the CNS of autistic patients. It should be noted that stem cells, such as fetal 
and mesenchymal stem cells, have their own inherent immunomodulatory properties 
150
 and paracrine effects 151 that could be beneficial in treating the immune system 
dysregulation and deranged cytokine levels seen in ASDs. The use of hematopoietic 
stem cells (HSCs) to achieve these effects is illustrated in Figure 8.  
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A recent open label proof of concept study, involving autologous bone marrow 
mononuclear cells intrathecally transplanted into 32 patients with autism, 
successfully demonstrated improvements in various parameters associated with 
ASDs – including social and emotional responsiveness, communication and 
behavior. The therapy was also found to be safe, with three patients experiencing 
adverse side effects that were controlled with medication 152,153.  
 
Ichim et al. have proposed that combination therapies using MSCs and cord blood 
cells could have a better outcome for autism treatment, as they could target both the 
immune dysregulation and neural hypoperfusion aspects of the molecular pathology 
in ASDs.144 This idea is based on the promising phase III results of using 
mesenchymal stem cells against immune dysregulation in Crohn's disease, and 
positive effects of cord blood CD34+ cells as potent angiogenic stimulators in 
peripheral and cerebral ischemia. In fact, a non-randomized, open-label, single 
center phase I/II trial evaluated efficacy and safety of combined transplantation of 
human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem 
cells (MSCs) in treatment of autistic children.154 The treatment was found to improve 
emotional and intellectual responses, adaptation to change, non-verbal 
communication, social withdrawal, stereotypic behavior, hyperactivity and 
inappropriate speech. The treatment did not demonstrate any safety concerns. The 
authors have suggested increased brain perfusion and/or immune system regulation 
as plausible mechanisms for the observed treatment effects. Some studies have also 
demonstrated potential therapeutic benefit by reducing the BBB problems in ASDs 
using HSCs.139 
 
Conclusions and Future Directions 
 
In contemporary thought, neuropsychiatric disorders such as autism are often seen 
as the manifestation of dysfunctional genetic and brain development processes 
occurring during prenatal life. Yet evidence is increasingly pointing towards several 
non-genetic factors as having a crucial role during the prenatal period, and progress 
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is being made in linking these to genetic susceptibility, and ultimately to the 
neurodevelopmental abnormalities associated with autism. A better understanding of 
autism etiology could be attained by a more in-depth exploration of critical 
biochemical pathways/mechanisms - whilst a more detailed research focus on the 
prenatal environment may help resolve several outstanding diagnostic issues. 
Although there is much excitement surrounding the potential for pharmacological and 
stem cell intervention in the management of ASDs (Figure 9), such therapies remain 
in their infancy, and their current applications are largely experimental. However, 
with a greater fundamental understanding of ASDs and the neuropathological 
processes underlying them, such ideas could one day transform the ways in which 
we diagnose and manage autism in the clinical setting – and perhaps offer, for the 
first time, a definitive treatment. 
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Captions 
 
 
Figure 1 represents the sequential discussion of etiology, diagnosis and treatment in 
this review, which aims to fit together these different pieces of the autism “puzzle” to 
obtain a more complete understanding of the condition. 
 
Figure 2 shows the positive and negative regulation of RORA by estrogen and 
testosterone respectively, as well as the downstream effect of RORA expression on 
aromatase (CYP19A1). The stimulatory effect of estrogen on RORA expression may 
explain the four-fold lower incicdence of autism in females. 54 Reproduced with 
permission from Sarachana et al. Copyright © 2011 PLOS 
 
Figures 3A and 3B show the decreased expression of RORA and aromatase in the 
postmortem frontal cortices of autistic patients. Figure 3C shows the strong 
correlation between RORA and aromatase expression in frontal cortex neurons of 
autistic individuals in the same study, which is highly suggestive of a direct 
downstream effect of RORA on aromatase expression. 54 Reproduced with 
permission from Sarachana et al 2011. Copyright © 2011 PLOS 
 
Figure 4. Maternal IgG antibodies can cross the placenta and enter the developing 
brain of the fetus due to increased permeability of the immature BBB. These 
antibodies can the trigger local immune destruction of brain matter, contributing to 
the pathophysiology of autism. 103 Reproduced with permission from Braunschweig 
et al 2011. Copyright © 2011 AMA Publishing Group Journals. 
 
Figure 5. Vasu et al. found that the levels of eight thirteen miRNAs were 
downregulated while five were upregulated in autistic children. The amount of 
miRNA present was quantified using normalized cycle threshold (Ct) values.111 
Reproduced with permission from Vasu et al 2014. Copyright © 2014 BioMed 
Central Ltd. 
 
Figure 6 was obtained by fMRI and shows the brain areas that are activated above 
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the resting level when healthy and autistic subjects were exposed to an 
unpredictable tone in a sequence of otherwise predictable tones. There was 
markedly reduced cortical activation, especially in the frontal and temporal lobes, in 
autistic individuals, suggesting a compromised ability to process high-level auditory 
stimuli. This was accompanied by a compensatory increase in activation of the 
cerebellum, which has recently been implicated in sequence integration, time 
matching and error detection. This pattern of activation may provide a neural basis 
for resistance to unexpected changes in the environment in ASD children.121 
Reproduced with permission from Hugdahl et al 2012. Copyright © 2012 Co-Action 
Publishing. 
 
Figure 7. Panel A depicts brain sections from the periventricular white matter of a 
healthy rabbit kit (control) and rabbit kits with CP who were treated with PBS (acting 
as negative controls), 10mg/kg NAC (NAC_10), 100mg/kg NAC (NAC_100), 1mg/kg 
NAC-conjugated dendrimer and 10mg/kg NAC-conjugates dendrimer. Nuclei are 
stained with DAPI (blue), microglia are stained with lectin (red) while CD11b, which 
is a cell surface marker for the pro-inflammatory microglial phenotype, is stained with 
CD11b antibody (green).  Merged areas appear yellow, corresponding to pro-
inflammatory microglia which stain for both lectin and CD11b. Panel B shows the 
Western blot results for CD11b in the same subjects. Importantly, it can be seen that 
the use of dendrimers reduces the dose of NAC required, probably due to the 
selective accumulation of dendrimers in the brain.137 Reproduced with permission 
from Kannan et al 2012. Copyright © 2012 American Association for the 
Advancement of Science (AAAS). 
 
Figure 8 illustrates the use of HSCs to reduce pro-inflammatory and increase anti-
inflammatory cytokines, thereby suppressing the neuroinflammation that occurs in 
ASD. HSCs may also help recruit more tissue stem cells, positively reinforcing their 
therapeutic role. 139 Reproduced with permission from Siniscalco et al 2013. 
Copyright © 2013 Frontiers Media S.A. 
 
Figure 9 illustrates the general mechanism of action of some novel proposed 
therapies for ASDs, although these therapies are still in their infancy. 
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Abbreviations 
 
ADHD; attention deficit hyperactivity disorder  
APA; American Psychiatric Association 
AuNP; gold nanoparticle 
ASD; autism spectrum disorder 
BBB; blood-brain-barrier 
CDD; childhood disintegrative disorder 
CNS; central nervous system 
CNV; copy number variation 
CU; callous unemotional  
DSM-5; Diagnostic and Statistical Manual of Mental Disorders, 5th Edition 
fMRI; functional magnetic resonance imaging 
HSC; haematopoietic stem cell  
MRI; magnetic resonance imaging 
MSC; mesenchymal stem cell  
MVPA; multi-voxel pattern analysis 
OXTR; oxytocin receptor 
RORA; retinoic acid related orphan receptor alpha 
PAH; polyaromatic hydrocarbon 
PCB; polychlorinated biphenyls 
RTT; Rett syndrome 
TRP; tandem repeat polymorphism 
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